Cargando…

An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci

Genome-wide association studies (GWAS) have identified many variants associated with complex traits, but identifying the causal gene(s) is a major challenge. Here we present an open resource that provides systematic fine-mapping and gene prioritization across 133,441 published human GWAS loci. We in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mountjoy, Edward, Schmidt, Ellen M., Carmona, Miguel, Schwartzentruber, Jeremy, Peat, Gareth, Miranda, Alfredo, Fumis, Luca, Hayhurst, James, Buniello, Annalisa, Karim, Mohd Anisul, Wright, Daniel, Hercules, Andrew, Papa, Eliseo, Fauman, Eric B., Barrett, Jeffrey C., Todd, John A., Ochoa, David, Dunham, Ian, Ghoussaini, Maya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611956/
https://www.ncbi.nlm.nih.gov/pubmed/34711957
http://dx.doi.org/10.1038/s41588-021-00945-5
Descripción
Sumario:Genome-wide association studies (GWAS) have identified many variants associated with complex traits, but identifying the causal gene(s) is a major challenge. Here we present an open resource that provides systematic fine-mapping and gene prioritization across 133,441 published human GWAS loci. We integrate genetics (GWAS Catalog and UK Biobank) with transcriptomic, proteomic and epigenomic data, including systematic disease-disease and disease-molecular trait colocalization results across 92 cell types and tissues. We identify 729 loci fine-mapped to a single coding causal variant and colocalized with a single gene. We trained a machine learning model using the fine-mapped genetics and functional genomics data using 445 gold-standard curated GWAS loci to distinguish causal genes from neighboring, outperforming a naive distance-based model. Our prioritized genes were enriched for known approved drug targets (OR = 8.1, 95% CI: (5.7, 11.5)). These results are publicly available through a web portal (http://genetics.opentargets.org), enabling users to easily prioritize genes at disease-associated loci and assess their potential as drug targets.